Cyclerion Therapeutics, Inc. (CYCN)
Stock Price:
$2.50 USD
-0.08 (-3.10%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Pre-market: $2.54 +0.04 (1.60%) Oct 28, 4:20 AM
Key Info
| Market Cap |
84.80M |
| Revenue (ttm) |
4.64M |
| Net Income (ttm) |
-93.13M |
| Shares Out |
33.92M |
| EPS (ttm) |
-3.38 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$2.50 |
| Previous Close |
$2.58 |
| Change ($) |
-0.08 |
| Change (%) |
-3.10% |
| Day's Open |
2.56 |
| Day's Range |
2.47 - 2.59 |
| Day's Volume |
768,851 |
| 52-Week Range |
1.69 - 14.77 |
More Stats
| Market Cap |
84.80M |
| Enterprise Value |
80.93M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.92M |
| Float |
29.33M |
| EPS (basic) |
-3.38 |
| EPS (diluted) |
-3.38 |
| FCF / Share |
-3.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
937,901 |
| Short Ratio |
3.49 |
| Short % of Float |
3.20% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
18.27 |
| PB Ratio |
1.39 |
| Revenue |
4.64M |
| Operating Income |
-96.98M |
| Net Income |
-93.13M |
| Free Cash Flow |
-91.45M |
| Net Cash |
3.87M |
| Net Cash / Share |
0.11 |
| Gross Margin |
97.09% |
| Operating Margin |
-2,089.10% |
| Profit Margin |
-2,006.30% |
| FCF Margin |
-1,970.08% |
| ROA |
-31.28% |
| ROE |
-89.86% |
| ROIC |
-73.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.00
Current: $2.50
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 4.51 | - | - | - |
| Gross Profit | 4.51 | - | - | - |
| Operating Income | -125 | -115 | -93.92 | -63.55 |
| Net Income | -123 | -115 | -93.92 | -63.55 |
| Shares Outstanding | 27.38 | 27.38 | - | - |
| Earnings Per Share | -4.49 | -4.21 | - | - |
| Operating Cash Flow | -102 | -97.50 | -81.22 | -49.87 |
| Capital Expenditures | -6.72 | -3.44 | -1.40 | -1.45 |
| Free Cash Flow | -109 | -101 | -82.62 | -51.32 |
| Cash & Equivalents | 94.90 | - | - | - |
| Total Debt | 73.92 | - | - | - |
| Net Cash / Debt | 20.98 | - | - | - |
| Assets | 186 | 7.40 | 5.47 | 3.88 |
| Liabilities | 88.75 | 17.85 | 14.04 | 10.64 |
| Book Value | 97.73 | -10.45 | -8.57 | -6.76 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cyclerion Therapeutics, Inc. |
| Country |
United States |
| Employees |
94 |
| CEO |
Peter M. Hecht |
Stock Information
| Ticker Symbol |
CYCN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CYCN |
Description
Cyclerion Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.